Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...
With the European Medicines Agency identifying shortages in more than 30 critical medicines, the single market presents an opportunity to rethink ...
The 14-day Relative Strength Index (RSI) remains below the 50 level, signaling a strengthening bearish momentum. Additionally ...
On the downside, the GBP/USD pair could find immediate support at the nine-day EMA of 1.2597, followed by the 14-day EMA at 1 ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Mitsubishi Tanabe Pharma (MTPC) today announced that the European Medicines Agency (EMA) has accepted for review the ...